创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: In Vitro Assay Platform Main Features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-21 13:27
  • Views:

(Summary description)As a comprehensive platform integrating diversity, high throughput, automation and customized services, InnoModels Biotechnology In Vitro Assay Platform aims to provide accurate and reliable assay data for various scientific researches and to promote the research progress in the field of life sciences. This article will introduce the main features of the platform in detail.

InnoModels Biotechnology: In Vitro Assay Platform Main Features

(Summary description)As a comprehensive platform integrating diversity, high throughput, automation and customized services, InnoModels Biotechnology In Vitro Assay Platform aims to provide accurate and reliable assay data for various scientific researches and to promote the research progress in the field of life sciences. This article will introduce the main features of the platform in detail.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-21 13:27
  • Views:
Information

As a comprehensive platform integrating diversity, high throughput, automation and customized services, InnoModels Biotechnology In Vitro Assay Platform aims to provide accurate and reliable assay data for various scientific researches and to promote the research progress in the field of life sciences. This article will introduce the main features of the platform in detail.
1. Diversity: InnoModels Biotechnology in vitro assay platform covers a wide range of assay services, including but not limited to cytotoxicity, cell proliferation, cell migration and cell invasion. Whether it is basic cell biology research, or drug screening and development, the platform is able to provide a variety of assays and experimental programs to meet different research needs.
2. High-throughput and automation: The in vitro assay platform utilizes high-throughput and automated technologies that can handle a large number of samples simultaneously, increasing experimental efficiency and reducing human error. This high degree of automation allows researchers to quickly conduct large-scale experiments and accelerate the process of scientific research.

 


3. Customized services: The platform is able to provide customized services according to the specific needs of clients, ensuring that researchers can obtain personalized solutions that meet their experimental needs.
4. Strict quality control: The platform carries out strict quality control on all testing services to ensure the accuracy and reliability of experimental results.
In conclusion, with its advantages in detection services, high-throughput automation, customized services and quality control, the InnoModels Biotechnology in vitro assay platform and its sub-platforms provide researchers with efficient, accurate and reliable in vitro assay services. These platforms will help promote research advances in the life sciences and facilitate the development of drug discovery and disease treatment.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司